Pub. Date : 2022 May 26
PMID : 35616006
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. | asciminib | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 2 | Asciminib is a substrate of CYP3A4 and P-glycoprotein (P-gp) and possesses pH-dependent solubility in aqueous solution. | asciminib | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 3 | Asciminib is a substrate of CYP3A4 and P-glycoprotein (P-gp) and possesses pH-dependent solubility in aqueous solution. | asciminib | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 4 | The AUC of asciminib was marginally decreased by concomitant administration with the strong CYP3A inducer rifampicin (by ~13-15%) and the strong P-gp inhibitor quinidine (by ~13-16%). | asciminib | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 5 | Taking into account the large therapeutic window of asciminib, the observed changes in asciminib PK following multiple doses of P-gp, CYP3A inhibitors, CYP3A inducers, or ARAs are not considered to be clinically meaningful. | asciminib | ATP binding cassette subfamily B member 1 | Homo sapiens |